Exenatide

Exenatide is a GLP-1 receptor agonist derived from Gila monster saliva, primarily utilized for blood sugar control and weight management. While the substance is FDA-approved for Type 2 diabetes, community interest focuses on its application for weight loss and cardiovascular health. Users should note that the evidence base for these off-label indications is thinner than the current discourse suggests, as many exploratory uses lack posted results or rely on limited data. Because community reports are currently silent on adverse events, potential users should be aware that the clinical profile remains anchored to its primary metabolic indications.

Half-life~2.4 h

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.85.01.23.53.21.0

Research Evidence

Evidence shape

Exenatide carries a high tier of evidence, supported by extensive clinical literature primarily focused on the treatment of Type 2 Diabetes Mellitus. With over 260 registered trials and 100 distinct sponsors, the research base is broad and includes numerous blinded, high-quality studies confirming its metabolic effects. While the data is robust for glycemic control and weight management, the vast majority of the 85 mapped indications remain exploratory or limited to single-trial investigations, signaling that clinical consensus is concentrated heavily on its primary metabolic applications rather than its wide-ranging experimental uses.

Depthhow much
267 registered trials
213 completed · 105 with posted results · 5 recruiting / active · combined n=644271
Breadthhow many areas
85 indications mapped
19 with results · 60 thin / exploratory · 1 animal-only · 54 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
46 blinded with results · 102 distinct sponsors · AE rows aggregated from 86 trials · 75 linked publications on registered trials
Breadth and depth283 rows captured
Human
direct clinical signal
271
Animal
translational support
9
In vitro
mechanistic support
3
HighMediumLow

Anecdotal efficacy

Exenatide side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
CPC Scientific
USA/China
5 mg
$126.50
$25.3/mg

price offers can be sorted by column

EXENATIDE dosing & protocol

How EXENATIDE is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 216
Typical dose
10 µg5 µg – 2 mg
typical
0
500 µg
1 mg
1.5 mg
2 mg
distribution of 129 reported doses · darker = more
Frequency
twice daily
Route
subQ

In the research trials tier, exenatide was administered subcutaneously at 10 mcg twice daily, with doses ranging from 5 mcg to 2 mg.

216 sources
Clinician practice
Doctor & published-protocol guidance
Typical dose
—
0
500 µg
1 mg
1.5 mg
2 mg
no dose captured for this tier yet

No structured protocol details captured for this tier yet.

Anecdotal
Community-reported real-world use
Typical dose
—
0
500 µg
1 mg
1.5 mg
2 mg
no dose captured for this tier yet
Frequency
unspecified
Route
subQ

Regulatory safety notes

Warnings and precautions
  • • Acute Pancreatitis : Has been observed in patients treated with GLP-1 receptor agonists, including BYETTA. Discontinue if pancreatitis is suspected. • Never share a BYETTA pen between patients, even if the needle is changed. •
  • • Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Patients taking an insulin secretagogue or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Reduction in the dose of insulin secretagogues or insulin may…
  • • Acute Kidney Injury Due to Volume Depletion : Monitor renal function in patients reporting adverse reactions that could lead to volume depletion •
  • • Severe Gastrointestinal Adverse Reactions : Use has been associated with gastrointestinal adverse reactions, sometimes severe. BYETTA is not recommended in patients with severe gastroparesis. •
  • • Immunogenicity: Patients may develop antibodies to exenatide. If there is worsening glycemic control or failure to achieve target glycemic control, consider alternative antidiabetic therapy. •
  • • Hypersensitivity: Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue BYETTA and promptly seek medical advice. •
  • • Drug-induced Immune-mediated Thrombocytopenia: Serious bleeding which may be fatal has been reported. Discontinue BYETTA promptly and avoid re-exposure to exenatide. •
  • • Acute Gallbladder Disease: If cholelithiasis or cholecystitis are suspected, gallbladder studies are indicated. •
Contraindications
  • • BYETTA is contraindicated in
  • • patients with: • A prior severe hypersensitivity reaction to exenatide or to any of the excipients in BYETTA. Serious hypersensitivity reactions including anaphylaxis and angioedema have been reported with BYETTA [see W…
Drug interactions
  • • • May impact absorption of orally administered medications. (7) •
  • • Warfarin: Postmarketing reports of increased INR sometimes associated with bleeding. Monitor INR frequently until stable upon initiation or alteration of BYETTA therapy. (7) Generic Section Table 6: Clinically Relevant Interactions with BYETTA Concomitant Use…

Related peptides

SemaglutideTirzepatideRetatrutideSurvodutideAOD-9604CagrilintideOrforglipronLiraglutideTesamorelinEloralintideTesofensineMazdutide